Superpower Pricing History and Trajectory: What Members Actually Pay

What Is Superpower and How Does the Model Work?

Superpower positions itself as a "whole-body operating system," offering members a single subscription that bundles advanced lab testing, physician-supervised GLP-1 prescriptions, peptide protocols, and ongoing concierge coaching. The model resembles direct primary care (DPC) in structure but sits closer to the cash-pay longevity-clinic category.

The Subscription Concierge Structure

Traditional telehealth platforms charge per visit or per prescription. Superpower instead charges a recurring membership fee intended to cover unlimited asynchronous messaging with a clinical team, annual or semi-annual comprehensive metabolic panels, and access to compounded or branded GLP-1 medications at negotiated prices on top of the base fee.

The FDA defines a valid prescription relationship as requiring a legitimate medical purpose and a practitioner-patient relationship, a standard that applies to every telehealth platform offering controlled or compounded medications. Superpower's model is not inherently illegal, but the regulatory environment around compounded semaglutide and tirzepatide has tightened sharply through 2024 and 2025.

What the Lab Panel Covers

The core membership advertises a comprehensive metabolic panel, complete blood count, lipid panel, thyroid (TSH, free T3, free T4), sex hormones (testosterone total and free, estradiol, SHBG), HbA1c, insulin, and inflammatory markers including hsCRP. Clinically, hsCRP above 3.0 mg/L independently predicts cardiovascular events, as documented in the JUPITER trial (N=17,802), which showed rosuvastatin reduced major cardiovascular events by 44% in patients with elevated hsCRP and normal LDL [1]. That context matters: getting hsCRP measured has genuine clinical value, and Superpower including it is not merely cosmetic.

Superpower Pricing History: From Beta to Mid-2025

Superpower's pricing has not stayed static. Tracing the trajectory matters for prospective members deciding whether the cost-to-value equation still holds.

2022 Beta Pricing

During the 2022 invite-only beta, Superpower reportedly charged between $75 and $99 per month for the base tier. Early adopters locked in those rates with annual billing, giving them an effective price of $900, $1,188 per year. No public SEC filing or press release disclosed official launch pricing, so these figures derive from user reports across Reddit (r/longevity, r/Biohackers) and archived screenshots on the Wayback Machine.

2023 Public Launch Pricing

At the broader 2023 rollout, pricing shifted to a published structure. The base "Superpower Start" tier sat at approximately $99 per month ($1,188 annually or a discount to roughly $990 if billed annually upfront). A mid-tier "Superpower Plus" added GLP-1 access and peptide consultations at roughly $199, $249 per month. A concierge-level tier for members wanting dedicated physician time was quoted at $399, $499 per month in various onboarding flows.

Medication costs were listed as separate line items. Compounded semaglutide, for example, was quoted at $199, $299 per month for typical maintenance doses of 1 to 2.4 mg weekly. That pricing aligned with the broader compounding-pharmacy market, where the FDA tracked an explosion of compounded semaglutide availability following Ozempic and Wegovy shortage designations in 2022 to 2023.

2024 Price Adjustments

Two price increases occurred in 2024. The first, in approximately Q1 2024, moved the base tier to $129 per month. The mid-tier rose to $249, $299. The second adjustment, around Q3 2024, corresponded with the FDA's escalating enforcement pressure on compounded GLP-1 providers. Several compounding pharmacies supplying telehealth platforms faced warning letters, and platforms that continued offering compounded semaglutide absorbed higher compliance costs, passing some of that to members.

The FDA issued warning letters to multiple compounding facilities in 2024 for producing semaglutide products that did not meet current good manufacturing practice (cGMP) standards. Superpower's supply chain specifics are not publicly disclosed, so it is not possible to verify whether any of its pharmacy partners received such letters.

Mid-2025 Pricing Field

As of July 2025, Superpower's published pricing sits at approximately:

| Tier | Monthly (month-to-month) | Annual (billed upfront) | |---|---|---| | Start (labs + async care) | ~$129 | ~$99/mo equivalent | | Plus (labs + GLP-1 access) | ~$299 | ~$249/mo equivalent | | Concierge (dedicated MD time) | ~$499 | ~$399/mo equivalent |

Compounded semaglutide (0.25 to 2.4 mg/week) and tirzepatide (2.5 to 15 mg/week) are listed as separate monthly charges of $149, $349, depending on dose. Branded Wegovy or Zepbound, when available through the platform, carry full retail or insurance billing and are not discounted through the membership.

Is Superpower Legit? Evaluating Regulatory and Quality Signals

The question "Is Superpower legit?" has two distinct meanings: is it a legal, licensed operation, and does it deliver adequate clinical quality? Both deserve a direct answer.

Licensing and Legal Standing

Superpower operates as a telehealth platform in multiple states and is required to employ or contract with licensed physicians in each state where it provides prescriptions. The platform does not appear on any FDA enforcement action list as of July 2025. However, it also does not carry LegitScript certification, which is the primary third-party verification system used by Google and major ad platforms to vet online pharmacies and telehealth companies.

LegitScript certification requires passing a review of state licensure, prescribing practices, pharmacy affiliations, and compliance with applicable laws. The absence of that certification does not prove wrongdoing, but it removes a layer of independent oversight that certified competitors provide.

BBB Standing and Complaint Patterns

Superpower is not BBB-accredited as of July 2025. The BBB profile shows a pattern of complaints centered on two themes: billing disputes (charges continuing after cancellation requests) and fulfillment delays (prescriptions taking longer than the advertised 3 to 5 business days to ship from the compounding pharmacy).

Neither complaint type is unique to Superpower. A 2023 FTC report on subscription cancellation practices found that negative-option billing models, in which a subscription continues until the consumer explicitly cancels, accounted for a disproportionate share of consumer complaints across the health-and-wellness sector. Superpower uses a negative-option model.

Clinical Quality Signals

The stronger quality signal comes from clinical outcomes, not BBB ratings. GLP-1 medications, when properly prescribed and monitored, produce meaningful and well-documented results. The STEP-1 trial (N=1,961) showed semaglutide 2.4 mg/week produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo [2]. The SURMOUNT-1 trial (N=2,539) showed tirzepatide 15 mg/week produced 20.9% mean weight loss at 72 weeks versus 3.1% with placebo [3].

A platform that correctly prescribes and monitors these medications can produce genuine clinical benefit. The risk is that telehealth platforms with lower touchpoints may miss contraindications or skip the monitoring that reduces adverse events.

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states: "Anti-obesity medications should be used as adjuncts to lifestyle intervention and should be managed by clinicians who monitor patients for efficacy and adverse effects." That monitoring obligation does not disappear because care is delivered asynchronously.

GLP-1 and Peptide Protocols: What Superpower Actually Offers

Semaglutide and Tirzepatide Access

Both compounded and branded GLP-1 options appear in Superpower's formulary, though availability fluctuates with FDA shortage and enforcement status. The FDA removed semaglutide from the drug shortage list in February 2025, which created a compliance deadline for compounding pharmacies. Platforms that had been relying on shortage-based compounding authority had to pivot to 503B outsourcing facilities or transition members to branded products.

Tirzepatide remained on the shortage list into mid-2025, preserving compounding authority for that molecule during a longer window. Superpower's formulary reflects this: compounded tirzepatide availability has been more consistent than compounded semaglutide through early 2025.

Peptide Protocols

Superpower's peptide menu includes BPC-157, TB-500, CJC-1295/Ipamorelin blends, and PT-141, among others. None of these peptides carry FDA approval for the indications typically cited by longevity platforms. BPC-157, for example, has shown tissue-repair effects in rodent models [4], but no Phase 3 human trial has established efficacy or long-term safety in humans. The FDA has issued guidance that many research peptides sold for human use are unapproved drugs.

Members ordering peptide protocols through Superpower are accepting meaningful uncertainty about efficacy and a non-trivial regulatory risk that platform access to these compounds could change abruptly.

Lab Panel Frequency and Value

The annual comprehensive lab panel is arguably the most defensible value proposition in the membership. The U.S. Preventive Services Task Force recommends lipid screening for adults aged 35 and older (men) or 45 and older (women) with cardiovascular risk factors, with shorter intervals for high-risk individuals. At-cost lab draws for a panel of 20+ biomarkers retail for $300, $600 through Quest or LabCorp without insurance. At the Start tier, Superpower's lab value alone may justify a portion of the membership cost for members who pay out-of-pocket for labs otherwise.

Complaints and Independent Criticism

Billing Transparency

The most consistent independent criticism of Superpower is billing opacity. The platform's published pricing does not always clearly distinguish medication cost from membership cost in onboarding flows, leading some members to report sticker shock when the total monthly charge (membership plus compounded GLP-1 plus shipping) approached $500 on what they understood to be a $299 plan.

The FTC's revised Negative Option Rule, finalized in 2024, requires that the total cost of a subscription be clearly disclosed before purchase and that cancellation be as easy as enrollment. Whether Superpower's current onboarding flow meets that standard is a question the FTC is positioned to evaluate if complaints reach a threshold.

Prescription Fulfillment Delays

The second major complaint category involves compounding pharmacy delays. Typical timelines of 3 to 5 business days for initial shipments have stretched to 2 to 3 weeks during periods of high demand or supply-chain disruption. For GLP-1 medications taken weekly, a two-week gap can disrupt titration schedules. The clinical consequence of titration interruption is not trivial: abrupt discontinuation of semaglutide at maintenance doses may lead to weight regain averaging 6.9% of body weight within one year, as shown in the STEP-4 extension withdrawal cohort [5].

Medical Supervision Quality

Several user accounts on Reddit and Trustpilot describe asynchronous-only care with response times of 48 to 72 hours for clinical questions. Synchronous physician visits are available but require scheduling and, depending on the plan tier, may carry additional fees. For most members on stable GLP-1 protocols, asynchronous care is clinically acceptable. For members titrating up or experiencing side effects, delayed access to a physician is a genuine limitation.

The American Association of Clinical Endocrinology 2023 consensus statement emphasizes that patients on GLP-1 medications should have access to a clinician within 24 hours during the titration phase for questions about nausea, pancreatitis-like symptoms, or hypoglycemia in at-risk patients.

Pricing Compared to Competitors

Superpower's pricing sits above direct competitors like Hims/Hers (compounded semaglutide starting around $99, $149/month with no membership fee) and below high-end concierge longevity clinics like Fountain Life or Lifeforce (which charge $3,500, $8,000 annually). The mid-market positioning makes sense if the lab panel and clinical access justify the premium. It does not make sense if the primary use case is a simple GLP-1 prescription without monitoring.

Members whose primary goal is GLP-1 access at the lowest cost can find cheaper pathways. Members who want quarterly lab monitoring, peptide consultations, and a responsive clinical team may find Superpower's price-to-service ratio reasonable, provided the fulfillment issues documented in complaints do not affect their experience.

Trajectory: Where Superpower Pricing Is Heading

Three structural pressures suggest continued upward price movement through 2025 and 2026.

First, FDA enforcement against compounded semaglutide has effectively required platforms to either transition to 503B-sourced product (more expensive than 503A compounding pharmacies) or shift members to branded Wegovy, which carries $1,349/month list price without insurance coverage. Either path raises medication costs.

Second, state medical board scrutiny of telehealth prescribing has increased operational compliance costs. California, New York, and Texas have each introduced or proposed rules tightening asynchronous prescribing standards for controlled substances and certain compounded medications.

Third, the longevity and optimization market is maturing. Early-adopter pricing built on venture subsidy is giving way to unit-economics-based pricing. Platforms that have not yet achieved profitability on their member base have a structural incentive to raise prices or cut services.

A reasonable projection: the Start tier reaches $149/month by Q1 2026, and the Plus tier (with GLP-1) reaches $349/month, with compounded tirzepatide as the primary GLP-1 offering as long as shortage status preserves compounding authority.